Duchenne muscular dystrophy (DMD) is a lethal X-linked recessive muscle disease due to defect on the gene encoding dystrophin. The lack of a functional dystrophin in muscles results in the fragility of the muscle fiber membrane with progressive muscle weakness and premature death. There is no cure for DMD and current treatment options focus primarily on respiratory assistance, comfort care, and delaying the loss of ambulation. Recent works support the idea that stem cells can contribute to muscle repair as well as to replenishment of the satellite cell pool. Here we tested the safety of autologous transplantation of muscle-derived CD133+ cells in eight boys with Duchenne muscular dystrophy in a 7-month, double-blind phase I clinical trial. Stem cell safety was tested by measuring muscle strength and evaluating muscle structures with MRI and histological analysis. Timed cardiac and pulmonary function tests were secondary outcome measures. No local or systemic side effects were observed in all treated DMD patients. Treated patients had an increased ratio of capillary per muscle fibers with a switch from slow to fast myosin-positive myofibers.

Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients / Y. Torrente, M. Belicchi, C. Marchesi, G. Dantona, F. Cogiamanian, F. Pisati, M. Gavina, R. Giordano, R. Tonlorenzi, G. Fagiolari, C. Lamperti, L. Porretti, R. Lopa, M. Sampaolesi, L. Vicentini, N. Grimoldi, F. Tiberio, V. Songa, P. Baratta, A. Prelle, L. Forzenigo, M. Guglieri, O. Pansarasa, C. Rinaldi, V. Mouly, G.S. Butler Browne, G.P. Comi, P. Biondetti, M. Moggio, S.M. Gaini, N. Stocchetti, A. Priori, M.G. D'Angelo, A. Turconi, R. Bottinelli, G. Cossu, P. Rebulla, N. Bresolin. - In: CELL TRANSPLANTATION. - ISSN 0963-6897. - 16:6(2007), pp. 563-577. [10.3727/000000007783465064]

Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients

Y. Torrente
;
M. Belicchi;C. Marchesi;M. Guglieri;G.P. Comi;S.M. Gaini;N. Stocchetti;A. Priori;G. Cossu;N. Bresolin
Ultimo
2007

Abstract

Duchenne muscular dystrophy (DMD) is a lethal X-linked recessive muscle disease due to defect on the gene encoding dystrophin. The lack of a functional dystrophin in muscles results in the fragility of the muscle fiber membrane with progressive muscle weakness and premature death. There is no cure for DMD and current treatment options focus primarily on respiratory assistance, comfort care, and delaying the loss of ambulation. Recent works support the idea that stem cells can contribute to muscle repair as well as to replenishment of the satellite cell pool. Here we tested the safety of autologous transplantation of muscle-derived CD133+ cells in eight boys with Duchenne muscular dystrophy in a 7-month, double-blind phase I clinical trial. Stem cell safety was tested by measuring muscle strength and evaluating muscle structures with MRI and histological analysis. Timed cardiac and pulmonary function tests were secondary outcome measures. No local or systemic side effects were observed in all treated DMD patients. Treated patients had an increased ratio of capillary per muscle fibers with a switch from slow to fast myosin-positive myofibers.
autologous stem cell transplantation ; muscular dystrophy ; CD133
Settore MED/26 - Neurologia
Settore MED/27 - Neurochirurgia
Settore MED/41 - Anestesiologia
2007
Article (author)
File in questo prodotto:
File Dimensione Formato  
000000007783465064.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 249.87 kB
Formato Adobe PDF
249.87 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/42534
Citazioni
  • ???jsp.display-item.citation.pmc??? 71
  • Scopus 202
  • ???jsp.display-item.citation.isi??? 25
social impact